Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
Vaxcyte (Nasdaq: PCVX), a clinical-stage vaccine innovation company, has announced its participation in the Guggenheim SMID Cap Biotech Conference in New York. The company's management will engage in a fireside chat scheduled for Thursday, February 6, 2025 at 9:30 a.m. ET / 6:30 a.m. PT.
Investors and interested parties can access a live webcast of the presentation through the Investors & Media section of Vaxcyte's website at investors.vaxcyte.com. The webcast recording will remain available for approximately 30 days after the conference.
Vaxcyte (Nasdaq: PCVX), una compagnia innovativa nel campo dei vaccini in fase clinica, ha annunciato la sua partecipazione al Guggenheim SMID Cap Biotech Conference a New York. La direzione dell'azienda parteciperà a una chiacchierata informale prevista per giovedì 6 febbraio 2025 alle 9:30 ET / 6:30 PT.
Gli investitori e le parti interessate possono accedere a una diretta webcast della presentazione attraverso la sezione Investitori & Media del sito web di Vaxcyte all'indirizzo investors.vaxcyte.com. La registrazione della webcast rimarrà disponibile per circa 30 giorni dopo la conferenza.
Vaxcyte (Nasdaq: PCVX), una compañía innovadora en vacunas en etapa clínica, ha anunciado su participación en la Guggenheim SMID Cap Biotech Conference en Nueva York. La dirección de la empresa participará en una charla informal programada para jueves 6 de febrero de 2025 a las 9:30 a.m. ET / 6:30 a.m. PT.
Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de Inversores y Medios en el sitio web de Vaxcyte en investors.vaxcyte.com. La grabación de la transmisión permanecerá disponible durante aproximadamente 30 días después de la conferencia.
백사이티 (Nasdaq: PCVX)는 임상 단계의 백신 혁신 기업으로, 뉴욕에서 열리는 구겐하임 SMID 캡 생명공학 컨퍼런스에 참여한다고 발표했습니다. 회사의 경영진은 2025년 2월 6일 목요일 오전 9:30 ET / 오전 6:30 PT에 예정된 파이어사이드 채팅에 참여할 예정입니다.
투자자 및 관심 있는 분들은 Vaxcyte 웹사이트의 투자자 및 미디어 섹션을 통해 발표의 라이브 웹캐스트에 접근할 수 있습니다. 웹캐스트 녹화는 컨퍼런스 종료 후 약 30일 동안 이용 가능합니다.
Vaxcyte (Nasdaq: PCVX), une entreprise innovante dans le domaine des vaccins en phase clinique, a annoncé sa participation à la Guggenheim SMID Cap Biotech Conference à New York. La direction de l'entreprise participera à une discussion informelle prévue pour le jeudi 6 février 2025 à 9h30 ET / 6h30 PT.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section Investisseurs & Médias du site de Vaxcyte à l'adresse investors.vaxcyte.com. L'enregistrement du webinaire restera disponible pendant environ 30 jours après la conférence.
Vaxcyte (Nasdaq: PCVX), ein innovatives Unternehmen im Bereich klinische Impfstoffe, hat seine Teilnahme an der Guggenheim SMID Cap Biotech Conference in New York bekannt gegeben. Das Management des Unternehmens wird am Donnerstag, den 6. Februar 2025 um 9:30 Uhr ET / 6:30 Uhr PT an einem Fireside-Chat teilnehmen.
Investoren und Interessierte können über den Bereich Investoren & Medien auf der Website von Vaxcyte unter investors.vaxcyte.com auf einen Live-Webcast der Präsentation zugreifen. Die Aufzeichnung des Webcasts wird etwa 30 Tage nach der Konferenz verfügbar bleiben.
- None.
- None.
SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference in New York on Thursday, February 6, 2025 at 9:30 a.m. ET / 6:30 a.m. PT.
A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. VAX-31 is a 31-valent, carrier-sparing PCV being developed for the prevention of IPD in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.
Contacts:
Jennifer Zibuda, Senior Director, Investor Relations
Vaxcyte, Inc.
860-729-8902
investors@vaxcyte.com
FAQ
When is Vaxcyte (PCVX) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors watch Vaxcyte's (PCVX) Guggenheim Conference presentation?
How long will Vaxcyte's (PCVX) Guggenheim Conference presentation be available for replay?
What type of presentation will Vaxcyte (PCVX) give at the Guggenheim SMID Cap Biotech Conference?
